Literature DB >> 25170631

HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics.

C Prussing1, C Chan1, J Pinchoff1, L Kersanske1, K Bornschlegel1, S Balter1, A Drobnik1, J Fuld1.   

Abstract

Using surveillance data, we describe the prevalence and characteristics of individuals in New York City (NYC) co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Surveillance databases including persons reported to the NYC Department of Health and Mental Hygiene with HIV, HBV, and HCV by 31 December 2010 and not known to be dead as of 1 January 2000, were matched with 2000-2011 vital statistics mortality data. Of 140 606 persons reported with HIV, 4% were co-infected with HBV only, 15% were co-infected with HCV only, and 1% were co-infected with HBV and HCV. In all groups, 70-80% were male. The most common race/ethnicity and HIV transmission risk groups were non-Hispanic blacks and men who have sex with men (MSM) for HIV/HBV infection, and non-Hispanic blacks, Hispanics, and injection drug users for HIV/HCV and HIV/HBV/HCV infections. The overall age-adjusted 2000-2011 mortality was higher in co-infected than HIV mono-infected individuals. Use of population-based surveillance data provided a comprehensive characterization of HIV co-infection with HBV and HCV. Our findings emphasize the importance of targeting HIV and viral hepatitis testing and prevention efforts to populations at risk for co-infection, and of integrating HIV and viral hepatitis care and testing services.

Entities:  

Keywords:  surveillance

Mesh:

Year:  2014        PMID: 25170631      PMCID: PMC9507198          DOI: 10.1017/S0950268814002209

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  30 in total

1.  Epidemiology of the viral hepatitis-HIV syndemic in San Francisco: a collaborative surveillance approach.

Authors:  Melissa A Sanchez; Susan Scheer; Sue Shallow; Sharon Pipkin; Sandra Huang
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

2.  Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states.

Authors:  Suzanne Speers; R Monina Klevens; Candace Vonderwahl; Terry Bryant; Elaine Daniloff; Jeff Capizzi; Tasha Poissant; Aaron Roome
Journal:  Public Health Rep       Date:  2011 May-Jun       Impact factor: 2.792

Review 3.  HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.

Authors:  Lynn E Taylor; Tracy Swan; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2012-07       Impact factor: 9.079

4.  Hepatitis-B virus infection predicts mortality of HIV and hepatitis C virus coinfected patients.

Authors:  Ramón Teira
Journal:  AIDS       Date:  2013-03-13       Impact factor: 4.177

5.  Epidemiology of HIV infection in large urban areas in the United States.

Authors:  H Irene Hall; Lorena Espinoza; Nanette Benbow; Yunyin W Hu
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

6.  Clearance of hepatitis C virus after newly acquired infection in injection drug users.

Authors:  Marianne Jauncey; Joanne M Micallef; Stuart Gilmour; Janaki Amin; Peter A White; William Rawlinson; John M Kaldor; Ingrid van Beek; Gregory J Dore
Journal:  J Infect Dis       Date:  2004-08-18       Impact factor: 5.226

7.  Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.

Authors:  Lei Hua; Janet W Andersen; Eric S Daar; Marshall J Glesby; Kimberly Hollabaugh; Camlin Tierney
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

8.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Practical Considerations for Matching STD and HIV Surveillance Data with Data from Other Sources.

Authors:  Lori M Newman; Michael C Samuel; Mark R Stenger; Todd M Gerber; Kathryn Macomber; Jeffrey A Stover; Wendy Wise
Journal:  Public Health Rep       Date:  2009       Impact factor: 2.792

10.  Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.

Authors:  Vincent Thibault; Catherine Gaudy-Graffin; Philippe Colson; Joël Gozlan; Nathalie Schnepf; Pascale Trimoulet; Coralie Pallier; Karine Saune; Michel Branger; Marianne Coste; Francoise Roudot Thoraval
Journal:  Virol J       Date:  2013-03-15       Impact factor: 4.099

View more
  11 in total

Review 1.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.

Authors:  Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

2.  Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.

Authors:  Yun-Chi Chen; Chloe L Thio; Farin Kamangar; Andrea L Cox; Kjell J Wiberg
Journal:  J Viral Hepat       Date:  2020-08-02       Impact factor: 3.728

3.  Population-Based Estimates of Life Expectancy After HIV Diagnosis: United States 2008-2011.

Authors:  Azfar-E-Alam Siddiqi; H Irene Hall; Xiaohong Hu; Ruiguang Song
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

4.  Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence.

Authors:  Nina Pocuca; Jared W Young; David A MacQueen; Scott Letendre; Robert K Heaton; Mark A Geyer; William Perry; Igor Grant; Arpi Minassian
Journal:  Drug Alcohol Depend       Date:  2020-08-22       Impact factor: 4.492

5.  Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee.

Authors:  Toni Hall; Cathy A Jenkins; Todd Hulgan; Sally Furukawa; Megan Turner; Siddharth Pratap; Timothy R Sterling; Mohammad Tabatabai; Vladimir Berthaud
Journal:  AIDS Res Hum Retroviruses       Date:  2019-12-30       Impact factor: 2.205

6.  HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities.

Authors:  K A Bosh; J R Coyle; V Hansen; E M Kim; S Speers; M Comer; L M Maddox; S Khuwaja; W Zhou; A Jatta; R Mayer; A D Brantley; N W Muriithi; R Bhattacharjee; C Flynn; L Bouton; B John; J Keusch; C A Barber; K Sweet; C Ramaswamy; E F Westheimer; L VanderBusch; A Nishimura; A Vu; L Hoffman-Arriaga; E Rowlinson; A O Carter; L E Yerkes; W Li; J R Reuer; L J Stockman; T Tang; J T Brooks; E H Teshale; H I Hall
Journal:  Epidemiol Infect       Date:  2018-04-11       Impact factor: 2.451

Review 7.  A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Authors:  Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga
Journal:  J Assoc Nurses AIDS Care       Date:  2021 May-Jun 01       Impact factor: 1.809

8.  Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China.

Authors:  Mingze Su; Lingjie Liao; Hui Xing; Shuai Wang; Yutang Li; Wei Lu; Lingyuan He; Juan Deng; Yiming Shao; Tong Li; Hui Zhuang
Journal:  Infect Drug Resist       Date:  2018-10-02       Impact factor: 4.003

9.  Syndemic Characterization of HCV, HBV, and HIV Co-infections in a Large Population Based Cohort Study.

Authors:  Geoffrey McKee; Zahid A Butt; Stanley Wong; Travis Salway; Mark Gilbert; Jason Wong; Maria Alvarez; Nuria Chapinal; Maryam Darvishian; Mark W Tyndall; Mel Krajden; Naveed Z Janjua
Journal:  EClinicalMedicine       Date:  2018-11-05

10.  Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001-2012.

Authors:  Miranda S Moore; Angelica Bocour; Olivia C Tran; Baozhen Qiao; Maria J Schymura; Fabienne Laraque; Ann Winters
Journal:  Open Forum Infect Dis       Date:  2018-06-16       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.